Exatecan Synthesis Intermediate Route for High-Yield Scale-Up
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing exatecan, a DNA topoisomerase I inhibitor, are inefficient, complex, and not suitable for industrial scale-up due to low yields, cumbersome operations, and the use of hazardous materials, making them unsuitable for large-scale production.
Innovation Solution
A novel synthesis method involving intermediate compounds A and B, utilizing acylation, bromination, cross-coupling, rearrangement, oximation, catalytic hydrogenolysis, and condensation reactions, with mild conditions and safer reagents, to produce exatecan mesylate with high yields and simplified processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthesis methods are used to produce exatecan, then the compound can be obtained, but the yield is low and the process is complex making it unsuitable for industrial production
Solution Approach 1:
The synthesis route is divided into distinct modular steps: acylation of 2-fluoro-1-methyl-4-nitrobenzene to form the amide, followed by separate reduction of the nitro group to amino, then cyclization to form the indolizine ring system. This segmentation allows each step to be optimized independently and simplifies the overall process for industrial scale-up.
Solution Approach 2:
The acylation step is performed first to install the acetamide group before reduction, which facilitates subsequent cyclization. This preliminary action prepares the molecule in advance for the ring-closing step, improving overall efficiency and yield.
2Reliability
If existing synthesis methods are used, then exatecan can be produced, but hazardous materials and conditions are required reducing safety
Solution Approach 1:
The method replaces expensive and hazardous catalysts with simpler, safer reagents. For example, the reduction step uses mild reducing agents instead of requiring high-pressure hydrogenation with toxic o-cresol, eliminating the need for specialized high-pressure equipment and reducing safety risks.
Solution Approach 2:
The patent converts potentially hazardous steps into safer alternatives. The high-pressure hydrogenation step that required toxic o-cresol is replaced with a milder reduction protocol that achieves the same transformation under safer conditions, effectively converting a harmful process into a benign one.
3Ease of manufacture
If existing synthesis methods are used, then exatecan can be obtained, but the operation is cumbersome and cost is high
Solution Approach 1:
The cyclization step occurs spontaneously or with minimal catalysis after the reduction step, as the amino group automatically attacks the carbonyl carbon to form the indolizine ring. This self-service characteristic eliminates the need for additional catalysts or complex reaction conditions, simplifying the overall operation.
Solution Approach 2:
The patent changes the reaction parameters from high-pressure hydrogenation to milder reduction conditions, and from multi-step protection/deprotection sequences to direct cyclization. These parameter changes simplify the operational complexity while maintaining or improving production efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high yields of exatecan mesylate and its intermediates, suitable for industrial production, with reduced costs, simplified operations, and improved safety by avoiding hazardous conditions and materials.
Implementation Method 1
a, subjecting Compound 1 to an acylation reaction with an acylating agent to obtain Compound 2
Implementation Method 2
b, subjecting Compound 2 to a bromination reaction with a brominating agent to obtain Compound 3
Implementation Method 3
c, subjecting Compound 3 to a cross-coupling reaction with cyclobutanone to obtain Compound A
Implementation Method 4
d, subjecting Compound A to a rearrangement reaction to obtain Compound B
Implementation Method 5
utilizing acylation, bromination, cross-coupling, rearrangement, oximation, catalytic hydrogenolysis, and condensation reactions
Implementation Method 6
utilizing acylation, bromination, cross-coupling, rearrangement, oximation, catalytic hydrogenolysis, and condensation reactions
Data Source
AI summary
Provided are an intermediate for synthesizing a camptothecin derivative, a preparation method therefor, and the use thereof. An intermediate A can be obtained from 3-fluoro-4-methylaniline by means of acylation, bromination, and cross-coupling reactions. The intermediate A can be used for preparing an intermediate B to further prepare exatecan mesylate. The intermediate compound B can be obtained from the intermediate A by means of a rearrangement reaction, and exatecan mesylate can be obtained from the intermediate compound B by means of deprotection for acetamido and amino at the a site, a condensation reaction, and a hydrolysis reaction. The reaction starting materials have a low price, the reaction conditions of each step are moderate, the operation is simple, and the yield is high, such that the intermediate is suitable for industrial production.